united states of america
05 Dec 2025 06:00
ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025 (globenewswire)
Systemic activity of 35% ORR in 2L+ patients, including in patients with active brain metastases